LCAR-G08 cells therapy(Legend Biotech)

N/A

Report date: 2026/02/07 20:00:33

Base Information

Drug NameLCAR-G08 cells therapy(Legend Biotech)
Drug Alias NameChimeric Antigen Receptor (CAR)-T Cell Therapy Targeting Guanylyl Cyclase C (GCC)( Legend Biotech)LCAR-G08(LCAR)-G08
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-Heat-stable enterotoxin receptor
TargetsHeat-stable enterotoxin receptor
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesPeking UniversityNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPeking UniversityNanjing Legend Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsGastrointestinal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A